Last reviewed · How we verify

Isoflurane Volatile Liquid

Federal University of São Paulo · FDA-approved active Small molecule

Isoflurane is a volatile anesthetic that enhances inhibitory neurotransmission and suppresses excitatory signaling in the central nervous system to produce anesthesia.

Isoflurane is a volatile anesthetic that enhances inhibitory neurotransmission and suppresses excitatory signaling in the central nervous system to produce anesthesia. Used for General anesthesia for surgical procedures, Maintenance of anesthesia during surgery.

At a glance

Generic nameIsoflurane Volatile Liquid
Also known asisoflurane
SponsorFederal University of São Paulo
Drug classVolatile anesthetic
TargetGABA-A receptor, NMDA receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Isoflurane potentiates GABA-A receptor activity and inhibits NMDA glutamate receptors, leading to depression of neuronal activity and loss of consciousness. It also modulates other ion channels and neurotransmitter systems. The drug is administered by inhalation and rapidly crosses the blood-brain barrier to produce dose-dependent anesthetic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: